Ojemda
What Ojemda is used for
Ojemda is indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies (for biomarkers-based patient selection, see section 4.2)
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Ojemda
- Active substance
- tovorafenib
- Disease area
- Glioma
- Medicine group
- Antineoplastic agents
- ATC code
- L01EC04
- Marketing authorisation holder
- Ipsen Pharma
- Authorised in the EU since
- 2026
Official information
In the USA
Same active substance: Ojemda
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ojemda used for?
Ojemda is indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies (for biomarkers-based patient selection, see section 4.2)
What is the active substance in Ojemda?
Ojemda contains tovorafenib.
Who makes Ojemda?
The EU marketing authorisation holder is Ipsen Pharma.
Is Ojemda an orphan medicine?
Yes. Ojemda is designated an orphan medicine in the EU, for a rare disease (Glioma).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU